抗生物質耐性市場：タイプ別、作用機序別、活性スペクトル別、薬剤クラス別、投与経路別、エンドユーザー別、流通チャネル別-2025～2030年世界予測

抗生物質耐性市場は、2023年に90億2,000万米ドルと評価され、2024年には98億7,000万米ドルに達すると予測され、CAGR 9.40％で成長し、2030年には169億3,000万米ドルに達すると予測されています。

抗生物質耐性は、重要な公衆衛生問題であり、かつて感染症の治療に成功した薬剤の効果に抵抗する細菌やその他の微生物の能力を指します。この耐性は世界的に大きな脅威となっており、ヒトと動物の健康の両方に影響を及ぼし、農業、医療、経済の安定に大きな影響を与えます。抗生物質耐性に取り組む必要性は、一般的な治療が効かなくなり、病気の長期化や死亡率の増加につながる可能性があることにあります。新しいクラスの抗生物質が緊急に必要とされている医療や、政策変更によって責任ある使用が求められている農業など、その応用範囲は広いです。最終用途の主要セクターは、医療プロバイダー、製薬会社、規制機関です。

市場促進要因としては、薬剤耐性感染症の増加、抗生物質の慎重な使用を求める政府の取り組み、バクテリオファージや抗菌ペプチドのような代替治療法の研究開発に対する資金提供の増加などが挙げられます。バイオテクノロジー業界の技術革新、特に迅速診断ツールや個別化医療は、大きなビジネス機会の到来を予感させる。しかし、高コストや厳しい規制のために新しい抗生物質の開発ペースが遅いなどの制約が課題となっています。さらに、規制の緩い市場における抗生物質の誤用の可能性や、新しい治療法へのアクセスにおける世界の格差なども、成長に影響を与える要因です。

誤用を最小限に抑え、抗生物質の有効性を維持することができる迅速診断技術の強化や、プロバイオティクスやワクチンなどの代替療法の開発には多くの機会があります。企業への提言としては、共同研究開発への投資や、医薬品承認を迅速化するための支援的な政策枠組みの提唱などがあります。CRISPRを利用した標的抗菌薬の開発など、革新的な研究セグメントは特に有望です。市場は、技術の進歩や規制状況によって非常にダイナミックに動いており、新たな科学的ブレークスルーを活用しつつ、市場情勢を緩和することを目指す利害関係者にとって、緊急かつ好機的なセグメントとなっています。

市場力学：急速に進化する抗生物質耐性市場の主要市場洞察の解明

抗生物質耐性市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的領域にわたる様々なリスクを軽減することができ、また消費者行動や、それが製造コストや購買傾向に与える影響についてもより明確に理解することができます。

ポーターの5つの力：抗生物質耐性市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗生物質耐性市場における外部からの影響の把握

外部マクロ環境要因は、抗生物質耐性市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗生物質耐性市場における競合情勢の把握

抗生物質耐性市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス抗生物質耐性市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗生物質耐性市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗生物質耐性市場における成功への道筋を描く

抗生物質耐性市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：現在の市場環境についての詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セクターにおける拡大の可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを調査します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行えるよう、重要な質問にも回答しています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 抗生物質耐性感染症に関連する医療費の高騰が市場の成長に貢献
    • 迅速診断テストの採用増加が抗生物質耐性の市場需要を牽引
    • 製薬企業と研究機関の連携強化による抗生物質耐性ソリューション
    • 新興市場は抗生物質耐性ソリューションに大きな関心と可能性を示している
  • 抑制要因
    • 規制上のハードルと承認の遅れが新しい抗生物質の採用を妨げている
  • 機会
    • 重要な医療ニーズに対応するため、抗生物質耐性菌株を標的とした新規抗生物質の開発
    • 抗生物質耐性感染症の早期発見と管理のための高度な診断ツールの導入
    • バクテリオファージやプロバイオティクスなどの代替療法の探索による抗生物質耐性
  • 課題
    • 抗生物質調査における製薬会社と学術機関の連携不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗生物質耐性市場：タイプ別

• イントロダクション
• 抗菌製品
• 抗真菌製品
• 駆虫薬
• 抗ウイルス製品

第7章 抗生物質耐性市場：作用機序別

• イントロダクション
• 細胞壁合成阻害剤
• DNAジャイレース阻害剤
• タンパク質合成阻害剤
• RNAポリメラーゼ阻害剤

第8章 抗生物質耐性市場：活性スペクトル別

• イントロダクション
• 広域抗生物質
• 狭域抗生物質

第9章 抗生物質耐性市場：薬剤クラス別

• イントロダクション
• セファロスポリン
• フルオロキノロン
• マクロライド
• ペニシリン
• テトラサイクリン

第10章 抗生物質耐性市場：投与経路別

• イントロダクション
• 静脈内
• 経口

第11章 抗生物質耐性市場：エンドユーザー別

• イントロダクション
• クリニック
• 在宅医療
• 病院

第12章 抗生物質耐性市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第13章 南北アメリカの抗生物質耐性市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋の抗生物質耐性市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカの抗生物質耐性市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Aurobindo Pharma Limited
• 6. Bayer AG
• 7. Bristol-Myers Squibb Company
• 8. Cipla Limited
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline plc
• 12. Johnson & Johnson
• 13. Merck & Co., Inc.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. Roche Holding AG
• 17. Sanofi S.A.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ANTIBIOTIC RESISTANCE MARKET RESEARCH PROCESS
• FIGURE 2. ANTIBIOTIC RESISTANCE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 23. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 29. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIBIOTIC RESISTANCE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIBIOTIC RESISTANCE MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIBACTERIAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIFUNGAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIPARASITIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ANTIVIRAL PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DNA GYRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BROAD-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY NARROW-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 61. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 62. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. CANADA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 98. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 99. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 105. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 106. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. INDIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 225. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 226. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 227. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. ITALY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 251. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 253. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 254. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 255. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 257. POLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 258. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 260. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 261. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 262. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 264. QATAR ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY SPECTRUM OF ACTIVITY, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM ANTIBIOTIC RESISTANCE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 328. ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 329. ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2023

The Antibiotic Resistance Market was valued at USD 9.02 billion in 2023, expected to reach USD 9.87 billion in 2024, and is projected to grow at a CAGR of 9.40%, to USD 16.93 billion by 2030.

Antibiotic resistance, a critical public health issue, refers to the ability of bacteria and other microbes to resist the effects of drugs that once successfully treated infections. This resistance poses a significant threat globally, affecting both human and animal health, with substantial implications for agriculture, healthcare, and economic stability. The necessity for addressing antibiotic resistance lies in its potential to render common treatments ineffective, leading to prolonged illnesses and increased mortality. Applications are vast, including in healthcare, where new classes of antibiotics are urgently needed, and agriculture, where responsible usage is being driven by policy changes. The end-use sectors are largely healthcare providers, pharmaceutical companies, and regulatory bodies.

Market insights reveal key growth drivers such as the rising incidence of drug-resistant infections, governmental initiatives for prudent antibiotic use, and increased funding for R&D in alternative treatments like bacteriophages and antimicrobial peptides. The biotechnology industry's innovations, particularly in rapid diagnostic tools and personalized medicine, herald substantial opportunities. However, limitations such as the slow pace of new antibiotics development due to high costs and stringent regulations pose challenges. Additional factors affecting growth include the potential misuse of antibiotics in low-regulation markets and disparities in global access to new treatments.

Opportunities abound in enhancing rapid diagnostic technologies, which can minimize misuse and conserve antibiotic efficacy, and developing alternative therapies such as probiotics and vaccines. Recommendations for businesses include investing in collaborative R&D efforts and advocating for supportive policy frameworks to expedite drug approvals. Innovative research areas like harnessing CRISPR-based technologies for targeted antimicrobial therapies are particularly promising. The market is highly dynamic, driven by technological advancements and regulatory landscapes, presenting an urgent yet opportunistic field for stakeholders aiming to mitigate antibiotic resistance while capitalizing on emerging scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibiotic Resistance Market

The Antibiotic Resistance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High healthcare costs associated with antibiotic-resistant infections contributing to market growth
  • Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
  • Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
  • Emerging markets showing significant interest and potential in antibiotic resistance solutions
• Market Restraints
  • Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
• Market Opportunities
  • Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
  • Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
  • Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
• Market Challenges
  • Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research

Porter's Five Forces: A Strategic Tool for Navigating the Antibiotic Resistance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibiotic Resistance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibiotic Resistance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibiotic Resistance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibiotic Resistance Market

A detailed market share analysis in the Antibiotic Resistance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibiotic Resistance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibiotic Resistance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibiotic Resistance Market

A strategic analysis of the Antibiotic Resistance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibiotic Resistance Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibiotic Resistance Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Antibacterial Products, Antifungal Products, Antiparasitic Products, and Antiviral Products.
• Based on Mechanism of Action, market is studied across Cell Wall Synthesis Inhibitors, DNA Gyrase Inhibitors, Protein Synthesis Inhibitors, and RNA Polymerase Inhibitors.
• Based on Spectrum of Activity, market is studied across Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics.
• Based on Drug Class, market is studied across Cephalosporins, Fluoroquinolones, Macrolides, Penicillins, and Tetracyclines.
• Based on Route of Administration, market is studied across Intravenous and Oral.
• Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High healthcare costs associated with antibiotic-resistant infections contributing to market growth
    • 5.1.1.2. Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
    • 5.1.1.3. Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
    • 5.1.1.4. Emerging markets showing significant interest and potential in antibiotic resistance solutions
  • 5.1.2. Restraints
    • 5.1.2.1. Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
    • 5.1.3.2. Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
    • 5.1.3.3. Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibiotic Resistance Market, by Type

• 6.1. Introduction
• 6.2. Antibacterial Products
• 6.3. Antifungal Products
• 6.4. Antiparasitic Products
• 6.5. Antiviral Products

7. Antibiotic Resistance Market, by Mechanism of Action

• 7.1. Introduction
• 7.2. Cell Wall Synthesis Inhibitors
• 7.3. DNA Gyrase Inhibitors
• 7.4. Protein Synthesis Inhibitors
• 7.5. RNA Polymerase Inhibitors

8. Antibiotic Resistance Market, by Spectrum of Activity

• 8.1. Introduction
• 8.2. Broad-Spectrum Antibiotics
• 8.3. Narrow-Spectrum Antibiotics

9. Antibiotic Resistance Market, by Drug Class

• 9.1. Introduction
• 9.2. Cephalosporins
• 9.3. Fluoroquinolones
• 9.4. Macrolides
• 9.5. Penicillins
• 9.6. Tetracyclines

10. Antibiotic Resistance Market, by Route of Administration

• 10.1. Introduction
• 10.2. Intravenous
• 10.3. Oral

11. Antibiotic Resistance Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Homecare Settings
• 11.4. Hospitals

12. Antibiotic Resistance Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies

13. Americas Antibiotic Resistance Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Antibiotic Resistance Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Antibiotic Resistance Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Aurobindo Pharma Limited
• 6. Bayer AG
• 7. Bristol-Myers Squibb Company
• 8. Cipla Limited
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline plc
• 12. Johnson & Johnson
• 13. Merck & Co., Inc.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. Roche Holding AG
• 17. Sanofi S.A.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.